NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy, LLC, have entered a collaboration with ATMI, Inc., on a non-exclusive basis, to enable PCT and its affiliates to offer clients access to ATMI’s Integrity Xpansion technology platform. The Xpansion system will provide bioreactor expansion capability to help clients create and customize an appropriate development program to suit their needs.   The Xpansion system is part of ATMI’s LifeSciences Integrity family of single-use technologies an...